ANI Pharmaceuticals published an updated corporate investor presentation for November 2026 to its website. The presentation outlines the company's strategic transformation into a leading rare disease company, including its proposed acquisition of Egetis Therapeutics and growth strategies for products like Cortrophin Gel and ILUVIEN.
Ani Pharmaceuticals Sr. VP, General Counsel & Sec. Meredith Cook Sells $35.4K of Stock
Meredith Cook, Sr. VP, General Counsel & Sec., sold 500 shares of Ani Pharmaceuticals Inc at $70.80 a share, worth $35.4K in total on Nov 13, 2026. Shares held after the trade: 72,924 (-0.7%).